2
|
Tillmann S, Olschok K, Schröder SK, Bütow M, Baumeister J, Kalmer M, Preußger V, Weinbergerova B, Kricheldorf K, Mayer J, Kubesova B, Racil Z, Wessiepe M, Eschweiler J, Isfort S, Brümmendorf TH, Becker W, Schemionek M, Weiskirchen R, Koschmieder S, Chatain N. The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN. Cancers (Basel) 2021; 13:cancers13164210. [PMID: 34439364 PMCID: PMC8391615 DOI: 10.3390/cancers13164210] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2021] [Revised: 08/15/2021] [Accepted: 08/18/2021] [Indexed: 02/06/2023] Open
Abstract
Lipocalin 2 (LCN2), a proinflammatory mediator, is involved in the pathogenesis of myeloproliferative neoplasms (MPN). Here, we investigated the molecular mechanisms of LCN2 overexpression in MPN. LCN2 mRNA expression was 20-fold upregulated in peripheral blood (PB) mononuclear cells of chronic myeloid leukemia (CML) and myelofibrosis (MF) patients vs. healthy controls. In addition, LCN2 serum levels were significantly increased in polycythemia vera (PV) and MF and positively correlated with JAK2V617F and mutated CALR allele burden and neutrophil counts. Mechanistically, we identified endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) as a main driver of LCN2 expression in BCR-ABL- and JAK2V617F-positive 32D cells. The UPR inducer thapsigargin increased LCN2 expression >100-fold, and this was not affected by kinase inhibition of BCR-ABL or JAK2V617F. Interestingly, inhibition of the UPR regulators inositol-requiring enzyme 1 (IRE1) and c-Jun N-terminal kinase (JNK) significantly reduced thapsigargin-induced LCN2 RNA and protein expression, and luciferase promoter assays identified nuclear factor kappa B (NF-κB) and CCAAT binding protein (C/EBP) as critical regulators of mLCN2 transcription. In conclusion, the IRE1-JNK-NF-κB-C/EBP axis is a major driver of LCN2 expression in MPN, and targeting UPR and LCN2 may represent a promising novel therapeutic approach in MPN.
Collapse
Affiliation(s)
- Stefan Tillmann
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Kathrin Olschok
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Sarah K. Schröder
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
- Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany
| | - Marlena Bütow
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Julian Baumeister
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Milena Kalmer
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Vera Preußger
- Institute of Pharmacology and Toxicology, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany; (V.P.); (W.B.)
| | - Barbora Weinbergerova
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, 625 00 Brno, Czech Republic; (B.W.); (J.M.); (B.K.); (Z.R.)
| | - Kim Kricheldorf
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Jiri Mayer
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, 625 00 Brno, Czech Republic; (B.W.); (J.M.); (B.K.); (Z.R.)
| | - Blanka Kubesova
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, 625 00 Brno, Czech Republic; (B.W.); (J.M.); (B.K.); (Z.R.)
| | - Zdenek Racil
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, 625 00 Brno, Czech Republic; (B.W.); (J.M.); (B.K.); (Z.R.)
- Institute of Hematology and Blood Transfusion, 12820 Prague, Czech Republic
| | - Martina Wessiepe
- Institute of Transfusion Medicine, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany;
| | - Jörg Eschweiler
- Department of Orthopedic Surgery, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany;
| | - Susanne Isfort
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Tim H. Brümmendorf
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Walter Becker
- Institute of Pharmacology and Toxicology, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany; (V.P.); (W.B.)
| | - Mirle Schemionek
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Ralf Weiskirchen
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
- Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany
| | - Steffen Koschmieder
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
| | - Nicolas Chatain
- Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, 520674 Aachen, Germany; (S.T.); (K.O.); (M.B.); (J.B.); (M.K.); (K.K.); (S.I.); (T.H.B.); (M.S.); (S.K.)
- Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany; (S.K.S.); (R.W.)
- Correspondence: ; Tel.: +49-241-8037798
| |
Collapse
|
3
|
Imoto Y, Wakasaki A, Izumida K, Shimada H, Ohkubo K, Kawano Y, Ishikura H, Matsunaga A. Analysis of the diagnostic capabilities of urinary neutrophil gelatinase-associated lipocalin and serum procalcitonin for acute kidney injury at the early stage of critical care intensive care unit admission. J Clin Lab Anal 2021; 35:e23852. [PMID: 34101898 PMCID: PMC8274979 DOI: 10.1002/jcla.23852] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 05/09/2021] [Accepted: 05/10/2021] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Acute kidney injury (AKI) is a disease that negatively affects patient prognosis and requires early diagnosis and treatment. Biomarkers that predict AKI are needed for early diagnosis of this disease. METHODS We compared the AKI group and the non-AKI group in patients who were admitted to our critical care intensive care unit (ICU) and conducted a comparative study focusing on urinary neutrophil gelatinase-associated lipocalin (U-NGAL) and serum procalcitonin (PCT). RESULTS Seventy-one out of 106 ICU inpatients were diagnosed with AKI in accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Among the patients who were diagnosed with AKI stages 1 to 3, 94.4% of all patients reached the maximum stage by day 5 after admission. Comparing the non-AKI group and AKI stage 1 to 3 on days 1 to 3 after admission, U-NGAL and PCT levels in the stage 3 group were significantly higher than those in the non-AKI group. Additionally, in receiver operating characteristic curve (ROC) analysis on days 1-3 after admission, U-NGAL and PCT levels can be used as biomarkers for the diagnosis of AKI, and in particular, AKI stage 3 can be predicted and diagnosed with high accuracy. U-NGAL and PCT levels were also significantly higher in AKI due to sepsis and acute pancreatitis and due to sepsis, respectively. CONCLUSIONS Measuring U-NGAL and PCT levels as biomarkers for AKI may further improve the accuracy of AKI diagnosis in critical care ICU.
Collapse
Affiliation(s)
- Yuji Imoto
- Department of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan
| | - Ayano Wakasaki
- Department of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan
| | - Kumiko Izumida
- Department of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan
| | - Hiroshi Shimada
- Department of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan
| | - Kumiko Ohkubo
- Department of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan.,Department of Laboratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Yasumasa Kawano
- Department of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Hiroyasu Ishikura
- Department of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| | - Akira Matsunaga
- Department of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan.,Department of Laboratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
| |
Collapse
|
4
|
Cho CH, Cha J. Analysis of neutrophil gelatinase-associated lipocalin, vascular endothelial growth factor, and soluble receptor for advanced glycation end-products in bone marrow supernatant in hematologic malignancies. Clin Biochem 2020; 80:19-24. [PMID: 32304694 DOI: 10.1016/j.clinbiochem.2020.04.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 04/13/2020] [Accepted: 04/14/2020] [Indexed: 01/20/2023]
Abstract
BACKGROUND Inflammation is a known risk factor of cancer development, including inflammation-driven leukemogenesis. Evaluation of inflammation-related cytokines in early diagnosis stages is crucial to understand the development of hematologic malignancy. Our aim was to measure three cytokines- neutrophil gelatinase-associated lipocalin (NGAL), vascular endothelial growth factor (VEGF), and soluble receptor for advanced glycation end-products (sRAGE) in bone marrow (BM) samples from patients diagnosed with hematologic malignancy and compare these measurements with the control. Additionally, we evaluated whether NGAL was significantly associated with sRAGE, VEGF, and several hematological parameters. METHODS BM samples were collected from 73 patients, who were classified into myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), plasma cell neoplasm (PCN) and control groups according to the BM smear and pathology review. An immunoassay, a Luminex assay, and an enzyme-linked immunosorbent assay were used to quantitate NGAL, VEGF, and sRAGE, respectively, while all measurements of NGAL, VEGF and sRAGE were performed on BM supernatants. Data on hematological parameters were collected from medical records. Intergroup comparisons were performed using the Kruskal-Wallis H-test and Pearson Chi-Square test. Single and multiple regression analyses were performed to analyze the relationships among the parameters. RESULTS The independent factors associated with NGAL were neutrophil counts and VEGF. As for both NGAL and VEGF, the MPN (n = 23) group showed the highest level, while the MDS (n = 12) group showed low levels. NGAL levels in the AML (n = 13) and MDS groups were lower than in the control group (n = 14). The MPN group demonstrated higher VEGF levels than the AML and MDS groups. The MDS group showed lower VEGF levels than the PCN (n = 11) group. No statistical difference between the hematologic malignancy and control groups or among the hematologic malignancy groups was observed for sRAGE levels. CONCLUSION NGAL was related to neutrophil count and VEGF. NGAL and VEGF showed similar intergroup patterns, reflecting that NGAL was associated with VEGF.
Collapse
Affiliation(s)
- Chi-Hyun Cho
- Department of Laboratory Medicine, College of Medicine, Korea University Ansan Hospital, 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do 425-707, Republic of Korea.
| | - Jaehyung Cha
- Medical Science Research Center, Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Republic of Korea
| |
Collapse
|
5
|
Cho CH, Cha J, Chang EA, Nam MH, Park SJ, Sung HJ, Lee SR. Analysis of bone marrow supernatant neutrophil gelatinase-associated lipocalin and hematological parameters in hematological malignancy. J Clin Lab Anal 2020; 34:e23253. [PMID: 32091174 PMCID: PMC7307352 DOI: 10.1002/jcla.23253] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 01/28/2020] [Accepted: 01/30/2020] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Neutrophil gelatinase-associated lipocalin (NGAL) is a urine biomarker related to acute renal injury. Whereas several studies have evaluated NGAL levels in hematological malignancy, using peripheral blood (PB). Recently, bone marrow (BM) NGAL level was reported to be higher than PB NGAL level in individuals with hematological malignancy, suggesting that BM NGAL would reflect BM microenvironment better than PB NGAL. We measured BM NGAL levels in patients with hematological malignancy, comparing those with NGAL levels in normal BM. We evaluated the association of BM NGAL with hematological parameters including neutrophil counts. METHODS BM samples were collected from 107 patients who underwent BM examination. Immunoassays were used to assess NGAL levels. Data on hematological parameters were collected from medical records. Intergroup comparisons were performed using the Kruskal-Wallis H test and Pearson chi-square test. Single and multiple regression analyses were performed to analyze the relationships. RESULTS The independent factors that affected the BM NGAL level were neutrophil counts and BM band neutrophil%, while neutrophil count was the main influencing factor. The acute myeloid leukemia (n = 18) and myelodysplastic syndrome (n = 25) groups showed statistically lower BM NGAL levels than patients with normal BM. The myeloproliferative neoplasm group (n = 34) showed higher BM NGAL levels than patients with normal BM, but this difference was not statistically significant. Neutrophil counts and BM band neutrophil% showed intergroup patterns similar to those of BM NGAL levels. CONCLUSION BM NGAL was related to neutrophil count and BM band neutrophil%, showing different levels according to hematological malignant disease entities.
Collapse
Affiliation(s)
- Chi-Hyun Cho
- Department of Laboratory Medicine, College of Medicine, Korea University Ansan Hospital, Ansan-si, Korea
| | - Jaehyung Cha
- Medical Science Research Center, Korea University Ansan Hospital, Ansan-si, Korea
| | - Eun-Ah Chang
- Department of Laboratory Medicine, College of Medicine, Korea University Ansan Hospital, Ansan-si, Korea
| | - Myung-Hyun Nam
- Department of Laboratory Medicine, College of Medicine, Korea University Ansan Hospital, Ansan-si, Korea
| | - Seo-Jin Park
- Department of Laboratory Medicine, College of Medicine, Korea University Ansan Hospital, Ansan-si, Korea
| | - Hwa Jung Sung
- Department of Hematology, College of Medicine, Korea University Ansan Hospital, Ansan-si, Korea
| | - Se Ryeon Lee
- Department of Hematology, College of Medicine, Korea University Ansan Hospital, Ansan-si, Korea
| |
Collapse
|
6
|
Cho CH, Yoon J, Kim DS, Kim SJ, Sung HJ, Lee SR. Association of peripheral blood neutrophil gelatinase-associated lipocalin levels with bone marrow neutrophil gelatinase-associated lipocalin levels and neutrophil count in hematologic malignancy. J Clin Lab Anal 2019; 33:e22920. [PMID: 31090234 PMCID: PMC6642308 DOI: 10.1002/jcla.22920] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Revised: 04/12/2019] [Accepted: 04/28/2019] [Indexed: 01/25/2023] Open
Abstract
Background Although neutrophil gelatinase‐associated lipocalin (NGAL) is a biomarker for acute kidney injury, recently, high NGAL levels have been reported in hematologic malignancies. Given the mechanism underlying NGAL synthesis and secretion in neutrophilic series, it is speculated that NGAL levels are higher in bone marrow (BM) than in peripheral blood (PB). Additionally, PB NGAL levels are thought to be associated with neutrophilic parameters. We aimed to test both hypotheses in hematologic malignancies. Methods Paired BM and PB samples were collected from 41 patients undergoing BM examination for hematologic malignancies. NGAL levels were measured using immunoassays. Data on hematologic parameters were collected from medical records. Single and multiple regression analyses were performed to analyze the relationship. Results PB and BM NGAL (n = 41) levels were significantly different (163.0 ± 258.3 and 413.1 ± 616.2 ng/mL [mean ± standard deviation], respectively; P < 0.05). Simple regression analysis and multicollinearity assessment showed that BM NGAL levels, BM neutrophil%, and neutrophil count were significant predictors of PB NGAL. Two multiple regression models were developed (model 1, PB NGAL = 21.467* neutrophil count ‐ 0.785*BM neutrophil%; model 2, PB NGAL = 21.202*neutrophil count‐ 0.915*BM neutrophil% +0.10*BM NGAL). Akaike's information criterion and adjusted R2 values showed that model 1 had higher predictive accuracy for PB NGAL. In both models, neutrophil count was the only significant predictor. Conclusion BM NGAL was significantly higher than PB NGAL in hematologic malignancy. In addition, PB NGAL could be expressed as a multiple regression model including neutrophil count and BM neutrophil%, being significantly influenced by neutrophil count.
Collapse
Affiliation(s)
- Chi-Hyun Cho
- Department of Laboratory Medicine, College of Medicine, Korea University, Seoul, Korea
| | - Jung Yoon
- Department of Laboratory Medicine, College of Medicine, Korea University, Seoul, Korea
| | - Deok-Su Kim
- Department of Laboratory Medicine, College of Medicine, Korea University, Seoul, Korea
| | - Shin-Jong Kim
- Department of Laboratory Medicine, College of Medicine, Korea University, Seoul, Korea
| | - Hwa Jung Sung
- Department of Hematology, College of Medicine, Korea University, Seoul, Korea
| | - Se Ryeon Lee
- Department of Hematology, College of Medicine, Korea University, Seoul, Korea
| |
Collapse
|